Roxadustat Improves Erythropoietin Antibody-Mediated Pure Red Cell Aplasia in a Patient with Hemodialysis.
Blood Purif
; 51(2): 189-192, 2022.
Article
en En
| MEDLINE
| ID: mdl-34500449
ABSTRACT
Anemia is a common complication of chronic kidney disease (CKD). Recombinant human erythropoietin (rHu-EPO) is used extensively in patients with CKD. However, anti-erythropoietin (anti-EPO) antibody has been reported during rHu-EPO treatment, which causes pure red cell aplasia (PRCA). We presented a case of 75-year-old man, who underwent hemodialysis for 2 years. He developed PRCA during rHu-EPO treatment. The rHu-EPO was immediately discontinued, and the patient was given roxadustat treatment. After 6 months of roxadustat treatment, the anti-EPO antibody was disappeared, and hemoglobin recovered normal range. The results suggest that roxadustat can be used to treat patients with anti-EPO antibody-mediated PRCA without immunosuppressive therapy.
Palabras clave
Texto completo:
1
Bases de datos:
MEDLINE
Asunto principal:
Eritropoyetina
/
Aplasia Pura de Células Rojas
Tipo de estudio:
Etiology_studies
Límite:
Aged
/
Humans
/
Male
Idioma:
En
Revista:
Blood Purif
Año:
2022
Tipo del documento:
Article
País de afiliación:
China